The goal of the Functional Genomics Core (FGC) is to provide a comprehensive, integrated approach to genomics research for Cancer Center investigators. Presently, the FGC provides a range of Microarray and Data Analysis Services. The microarray gene expression profiling service is based on the Affymetrix oligonucleotide array platform of GeneChips. Basic and advanced data analysis is provided by biostatisticians and bioinformaticists in conjunction with the Biomedical Informatics Core. The FGC is currently undergoing expansion to provide two new major services, RNAi-based technology and genotyping. The former allows functional analyses of genes using approaches such as siRNA, and latter provides moderate-throughput SNP and DMA methylation analyses. All of the FGC services are provided by highly experienced Core Managers with extensive expertise in their areas of specialization. Cohesiveness and synergy among all of the FGC components are provided by the Scientific Director, who leads regular meetings with all Core Managers to discuss assay development, data analysis, trouble-shooting, integration, and new techniques. The Core Managers provide advice to investigators on experimental design prior to laboratory and clinical studies, assay development and quality control during the studies and interpretation of data generated by the Core. This """"""""one-stop shopping"""""""" approach makes functional genomics research more broadly accessible to Cancer Center investigators. Thus, the FGC provides advanced technologies and support for basic, clinical and population studies that enhance functional genomics research and collaborations across all COHCCC programs. During the prior 12-month reporting period, the FGC was used by 14 Cancer Center members from all 5 Research Programs;peer-reviewed usage represented 76% of the total. The proposed total annual budget is $339,788, representing 39% institutional support, 18% user fees, 16% other, and 27% ($91,000) requested from the CCSG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-29
Application #
8374895
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2013-04-24
Budget Start
2011-12-01
Budget End
2012-11-30
Support Year
29
Fiscal Year
2012
Total Cost
$60,728
Indirect Cost
$44,622
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Gu, Ying; Zhang, Jiawei; Ma, Xiaoxiao et al. (2017) Stabilization of the c-Myc Protein by CAMKII? Promotes T Cell Lymphoma. Cancer Cell 32:115-128.e7
Cao, Pengpeng; Mooney, Rachael; Tirughana, Revathiswari et al. (2017) Intraperitoneal Administration of Neural Stem Cell-Nanoparticle Conjugates Targets Chemotherapy to Ovarian Tumors. Bioconjug Chem 28:1767-1776
Mohanty, Suchismita; Mohanty, Atish; Sandoval, Natalie et al. (2017) Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines. Leuk Lymphoma 58:676-688
Wittenberg, Elaine; Ferrell, Betty; Koczywas, Marianna et al. (2017) Pilot Study of a Communication Coaching Telephone Intervention for Lung Cancer Caregivers. Cancer Nurs :
Yuan, Yuan; Vora, Nilesh; Sun, Can-Lan et al. (2017) Association of Pre-Chemotherapy Peripheral Blood Pro-Inflammatory and Coagulation Factors with Physical Function in Women with Breast Cancer. Oncologist 22:1189-1196
Deng, Ruishu; Hurtz, Christian; Song, Qingxiao et al. (2017) Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. Nat Commun 8:978
He, Zhiheng; Ma, Jian; Wang, Ruiqing et al. (2017) A two-amino-acid substitution in the transcription factor ROR?t disrupts its function in TH17 differentiation but not in thymocyte development. Nat Immunol 18:1128-1138
Kortylewski, Marcin; Moreira, Dayson (2017) Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities. Cancer Immunol Immunother 66:979-988
Somlo, George; Frankel, Paul H; Arun, Banu K et al. (2017) Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res 23:4066-4076
Slavin, Thomas P; Neuhausen, Susan L; Nehoray, Bita et al. (2017) The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. Fam Cancer :

Showing the most recent 10 out of 1277 publications